We are live on
!
Find out more
Westfield Capital Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
49.45%
This Fund
S&P 500
This Quarter
Est. Return
+6.64%
1 Year Est. Return
+49.45%
3 Year Est. Return
+148.08%
5 Year Est. Return
+180.9%
10 Year Est. Return
+972.24%
AUM
$13.4B
AUM Growth
+$421M
(+3.2%)
Cap. Flow
-$231M
Cap. Flow
% of AUM
-1.73%
Top 10 Holdings %
Top 10 Hldgs %
18.95%
Holding
286
New
38
Increased
90
Reduced
103
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$95.8M |
| 2 |
Mettler-Toledo International
MTD
|
+$89.4M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$66.9M |
| 4 |
Carnival Corporation Ltd
CCL
|
+$64.4M |
| 5 |
Walt Disney
DIS
|
+$62.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Steris
STE
|
+$102M |
| 2 |
Abbott
ABT
|
+$97.9M |
| 3 |
MGM Resorts International
MGM
|
+$97.5M |
| 4 |
Bank of America
BAC
|
+$90.9M |
| 5 |
Philip Morris
PM
|
+$88.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.01% |
| 2 | Healthcare | 16.54% |
| 3 | Industrials | 13.55% |
| 4 | Financials | 11.42% |
| 5 | Consumer Discretionary | 11.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Advanced Energy
AEIS
$13.7B
| $22.7M | 0.17% |
+390,873
| New | +$24.7M |
|
177
Alnylam Pharmaceuticals
ALNY
$29.2B
| $22.5M | 0.17% |
+228,140
| New | +$22.6M |
|
|
LNW
178
DELISTED
Light & Wonder
LNW
| $22.2M | 0.17% |
+452,680
| New | +$23.9M |
|
179
Camden Property Trust
CPT
$11B
| $21.6M | 0.16% |
237,495
-705
| -0.3% | -$61.4K |
|
|
SIVB
180
DELISTED
SVB Financial Group
SIVB
| $21.6M | 0.16% |
+74,694
| New | +$21.9M |
|
181
Watsco Inc
WSO
$13.8B
| $20.6M | 0.15% |
115,285
-26,910
| -19% | -$4.9M |
|
|
WNS
182
DELISTED
WNS Holdings
WNS
| $20.5M | 0.15% |
393,600
-228,025
| -37% | -$11.3M |
|
|
PPBI
183
DELISTED
Pacific Premier Bancorp
PPBI
| $20.3M | 0.15% |
532,352
-187,385
| -26% | -$7.64M |
|
184
Ciena
CIEN
$58.6B
| $19.9M | 0.15% |
751,661
-99,625
| -12% | -$2.53M |
|
|
EPAY
185
DELISTED
Bottomline Technologies Inc
EPAY
| $19.8M | 0.15% |
397,352
-168,430
| -30% | -$7.51M |
|
186
Kemper
KMPR
$1.72B
| $19.6M | 0.15% |
+259,327
| New | +$18.2M |
|
187
Green Dot
GDOT
$752M
| $18.4M | 0.14% |
250,588
+101,398
| +68% | +$6.99M |
|
188
Neurocrine Biosciences
NBIX
$17B
| $18.1M | 0.14% |
+184,741
| New | +$16.5M |
|
189
National Vision
EYE
$1.85B
| $17.9M | 0.13% |
489,395
+123,665
| +34% | +$4.31M |
|
|
CORV
190
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| $17.5M | 0.13% |
4,627,954
+435,920
| +10% | +$1.14M |
|
|
XENT
191
DELISTED
Intersect ENT, Inc
XENT
| $17.3M | 0.13% |
+461,532
| New | +$18.1M |
|
192
NovoCure
NVCR
$1.87B
| $16M | 0.12% |
509,610
+53,575
| +12% | +$1.49M |
|
193
Monolithic Power Systems
MPWR
$66.5B
| $15.5M | 0.12% |
115,690
+9,256
| +9% | +$1.18M |
|
194
Aclaris Therapeutics
ACRS
$825M
| $15M | 0.11% |
750,604
+40,235
| +6% | +$743K |
|
|
UCTT
195
Ultra Clean Holdings
UCTT
$3.81B
| $14.8M | 0.11% |
890,283
+84,667
| +11% | +$1.49M |
|
196
Lumentum
LITE
$66.8B
| $13.6M | 0.1% |
234,378
-8,153
| -3% | -$486K |
|
|
BPMC
197
DELISTED
Blueprint Medicines
BPMC
| $13.5M | 0.1% |
+212,980
| New | +$16.9M |
|
|
APLS
198
DELISTED
Apellis Pharmaceuticals
APLS
| $13.4M | 0.1% |
+606,956
| New | +$13.9M |
|
|
ACIA
199
DELISTED
Acacia Communications Inc
ACIA
| $13.3M | 0.1% |
+381,765
| New | +$12.5M |
|
|
KYNB
200
Kyntra Bio
KYNB
$28.3M
| $13.3M | 0.1% |
+8,467
| New | +$11M |
|
Similar funds
OAG
JG
CHP
SC
Westfield Capital Management's Q2 2018 Portfolio in Review
As of Q2 2018, Westfield Capital Management held 286 positions worth $13.4B, up 3.2% from $13B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Westfield Capital Management's Q2 2018 filing shows 38 new, 90 increased, 103 reduced and 43 closed positions. Its largest new stake was Bristol-Myers Squibb: 1,238,227 shares worth $68.5M. The largest sale was Steris, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 21% a quarter earlier, followed by Healthcare and Industrials.
- Westfield Capital Management's largest Q2 2018 buy was Bristol-Myers Squibb: 1,238,227 shares worth $68.5M.
- Westfield Capital Management added most to Thermo Fisher Scientific in Q2 2018, an estimated $95.8M increase.
- Westfield Capital Management's biggest Q2 2018 reduction was Steris, cutting an estimated $102M.
- Westfield Capital Management fully exited MGM Resorts International in Q2 2018, selling an estimated $97.5M.
- Westfield Capital Management's ten largest holdings make up 19% of its $13.4B portfolio in Q2 2018.
- Westfield Capital Management opened 38 new positions and closed 43 in Q2 2018.
- Westfield Capital Management's portfolio value rose 3.2% quarter-over-quarter to $13.4B.
Based on Westfield Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.